First, the market momentum for Mirum’s rare liver disease drug Livmarli should continue. Sales increased 56% year-over-year to $92.2 million in the third quarter of 2025. I believe that Livmarli is on …
3 Top Growth Stocks to Buy in the First Half of 2026
view original post